Mckesson Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
13.9%projected annual EPS growth
Analyst Coverage
15analysts covering
FY Revenue (est.)
$431.9Bnext fiscal year
FY EPS (est.)
$44.62next fiscal year
Monitoring Framework
Key Performance Indicators
U.S. Pharmaceutical Segment Revenue Quarterly90BTarget: Continued double-digit growth driven by specialty distribution and GLP-1 volumes
Adjusted Operating Margin Annually1.6%Target: Maintain or exceed 1.6% through operational leverage and automation
Oncology and Multispecialty Segment Operating Profit Growth Quarterly57.0%Target: Sustain high double-digit growth via strategic acquisitions and network expansion
Watch Items
- GLP-1 Distribution Revenue DecelerationTrigger: Sequential growth dropping below 5% or significant margin compression on GLP-1 productsAction: Re-evaluate top-line growth estimates and adjust specialty pharmaceutical segment valuation multiples.
- Medical-Surgical Solutions Segment SeparationTrigger: Delay in the planned IPO separation beyond the second half of calendar 2027Action: Assess impact on capital allocation, corporate focus, and sum-of-the-parts valuation models.
- Regulatory and Pricing Pressures (Inflation Reduction Act)Trigger: Implementation of direct Medicare drug price negotiations impacting high-volume specialty drugsAction: Review LIFO inventory charges, gross margin assumptions, and biopharma services segment profitability.
Research as of 2 Sep 2026